The Geography of Primary Hepatic Neoplasms Treatments in Canada: Changes in Latitudes and Changes in Attitudes

Figure 2

Temporal trends of the Standardized Incidence Ratio (SRI) and respective 95% confidence limits for treatment modalities of primary hepatic tumors in Canada over the period between 2002 and 2013. Over the study period, there were no significant temporal changes in SIRs for ablation, hepatic resection, or liver transplantation (a, b, c). On the other hand, transarterial locoregional therapies experienced a significant decline between the years 2004 and 2005 and national SIR remained below the expected value for all the following years (d). SRI values equal to 1.0 indicated that the treatment modality during the time period was equal to the expected countrywide average adjusted for population age and gender. SIR values more or less than 1.0 indicated that the treatment modality was above or below the expected countrywide average adjusted for age and gender. Statistically significant differences were identified when 95% confidence intervals of SIR did not include the value of 1.0 ( ≤ 0.05).

(a) Temporal trends of Standardized Incidence Ratio (SIR) of ablation therapies for primary hepatic tumors in Canada (2003–2013)

(b) Temporal trends of Standardized Incidence Ratio (SIR) of hepatic resections for primary hepatic tumors in Canada (2003–2013)

(c) Temporal trends of Standardized Incidence Ratio (SIR) of liver transplantation for primary hepatic tumors in Canada (2003–2013)

(d) Temporal trends of Standardized Incidence Ratio (SIR) of transarterial locoregional therapies for primary hepatic tumors in Canada (2003–2013)